

1 **Investigating the Association between Physical Health Comorbidities and Disability in**
2 **Individuals with Severe Mental Illness**

3 Luwaiza Mirza¹, Jayati Das-Munshi^{1,2}, Jaya Chaturvedi³, Honghan Wu^{4,5}, Zeljko Kraljetic³,
4 Tom Searle³, Shaweena Shaari¹, Aurelie Mascio³, Naoko Skiada³, Angus Roberts^{1,3,4,5},
5 Daniel Bean^{3,4}, Robert Stewart^{1,2}, Richard Dobson^{1,3,4,5}, Rebecca Bendayan^{1,3}

6 ¹NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust
7 and King's College London, London, United Kingdom

8 ²Department of Psychological Medicine, Institute of Psychiatry, Psychology and
9 Neuroscience, King's College London, London, United Kingdom

10 ³Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and
11 Neuroscience, King's College London, London, United Kingdom

12 ⁴Health Data Research UK London, University College London, London, United Kingdom

13 ⁵Institute of Health Informatics, University College London, London, United Kingdom

14

15 **Correspondence:** Rebecca Bendayan / ORCID: 0000-0003-1461-556X, E-mail:

16 rebecca.bendayan@kcl.ac.uk, NIHR Maudsley Biomedical Research Centre, Department of
17 Biostatistics & Health Informatics, SGDP Centre, IoPPN, Box PO 80, De Crespigny Park,
18 Denmark Hill, London SE5 8AF, UNITED KINGDOM

19

20 **Funding acknowledgements:** JD is funded by the Health Foundation working together with
21 the Academy of Medical Sciences, for a Clinician Scientist Fellowship and by the ESRC in
22 relation to the SEP-MD study [ES/S002715/1] and part supported by the ESRC Centre for

This peer-reviewed article has been accepted for publication but not yet copyedited or typeset, and so may be subject to change during the production process. The article is considered published and may be cited using its DOI.

This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.

Accepted manuscript: Authors' Copy

23 Society and Mental Health at King's College London [ESRC Reference: ES/S012567/1]. RB
24 is funded in part by grant MR/R016372/1 for the King's College London MRC Skills
25 Development Fellowship programme funded by the UK Medical Research Council (MRC)
26 and by grant IS-BRC-1215-20018 for the National Institute for Health Research (NIHR)
27 Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and
28 King's College London. HW is supported by Medical Research Council and Health Data
29 Research UK Grant (MR/S004149/1), Industrial Strategy Challenge Grant (MC_PC_18029)
30 and Wellcome Institutional Translation Partnership Award (PIII054). DMB is funded by a
31 UKRI Innovation Fellowship as part of Health Data Research UK MR/S00310X/1 (
32 <https://www.hdruk.ac.uk>). AM is funded by Takeda California, Inc. RD, RS, AR are part-
33 funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at
34 South London and Maudsley NHS Foundation Trust and King's College London. RD's work
35 is supported by 1. National Institute for Health Research (NIHR) Biomedical Research Centre
36 at South London and Maudsley NHS Foundation Trust and King's College London. 2. Health
37 Data Research UK, which is funded by the UK Medical Research Council, Engineering and
38 Physical Sciences Research Council, Economic and Social Research Council, Department of
39 Health and Social Care (England), Chief Scientist Office of the Scottish Government Health
40 and Social Care Directorates, Health and Social Care Research and Development Division
41 (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation
42 and Wellcome Trust. 3. The National Institute for Health Research University College
43 London Hospitals Biomedical Research Centre. This paper represents independent research
44 funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at
45 South London and Maudsley NHS Foundation Trust and King's College London and by the
46 Health Foundation. The views expressed are those of the author(s) and not necessarily those

47 of the NHS, the NIHR, the Department of Health, the MRC, ESRC or King's College
48 London.

49 **Abstract**

50 **Background:** Research suggests that an increased risk of physical comorbidities might have
51 a key role in the association between severe mental illness (SMI) and disability. We
52 examined the association between physical multimorbidity and disability in individuals with
53 SMI.

54 **Methods:** Data was extracted from the Clinical Record Interactive Search (CRIS) system at
55 South London and Maudsley Biomedical Research Centre (SLaM BRC). Our sample
56 (N=13,933) consisted of individuals who had received a primary or secondary SMI diagnosis
57 between 2007 and 2018 and had available data for **Health of Nations Outcome Scale**
58 **(HoNOS)** as disability measure. Physical comorbidities were defined using Chapters II-XIV
59 of the International Classification of Diagnoses (ICD-10).

60 **Results:** More than 60 % of the sample had complex multimorbidity. The most common
61 organ system affected were **neurological (34.7%)**, dermatological (15.4%) and circulatory
62 (14.8%). All specific comorbidities (ICD-10 Chapters) were associated with higher levels of
63 disability, HoNOS total scores. Individuals with musculoskeletal, skin/dermatological,
64 respiratory, endocrine, neurological, haematological or circulatory disorders were found to be
65 associated with significant difficulties associated with more than five HoNOS domains while
66 others had a lower number of domains affected.

67 **Conclusions:** Individuals with SMI and musculoskeletal, skin/dermatological, respiratory,
68 endocrine, neurological, haematological or circulatory disorders are at higher risk of
69 disability compared to those that do not have those comorbidities. Individuals with SMI and
70 physical comorbidities are at greater risk of reporting difficulties associated with activities of

71 daily living, hallucinations and cognitive functioning. Therefore, these should be targeted for
72 prevention and intervention programs.

73

74

75 **Introduction**

76 Providing personalized care to the growing number of individuals with multimorbidity (i.e., 2
77 or more physical health conditions) is one of the main challenges of our healthcare system
78 [1]. Traditional research on multimorbidity has focused on ageing populations, however there
79 is an urgent need to include younger populations which are known to have similar probability
80 of having multiple chronic health conditions when they are socially deprived [2, 3, 4] and/or
81 are from an ethnic minority groups [5, 6]. This has been highlighted as a key task to reduce
82 the mortality gap between individuals with severe mental illnesses (SMI), such as
83 schizophrenia or bipolar disorder, and the general population.

84 Individuals diagnosed with SMI, which includes schizophrenia-spectrum (SSD) and bipolar
85 disorders (BD), have also been reported to have a greater risk of comorbid physical health
86 conditions than individuals without SMI [7, 8]. In fact, this increased risk of chronic physical
87 morbidity (including cardiovascular, respiratory and infectious diseases, diabetes mellitus and
88 hypertension), has been suggested to underlie, at least in part, premature mortality in
89 individuals with SMI [9]. Specifically, patients with severe mental illness have been shown to
90 have standard mortality ratios that are more than 2 to 3-fold greater than the general
91 population, due to all-cause mortality, including suicide [10].

92 Moreover, disability associated with mental illness contributes significantly to the global
93 burden of disease, with schizophrenia being described as the mental disorder causing the
94 most disability globally [11,12]. Research in normative population has shown that
95 multimorbidity is associated with an increased likelihood of disability [13] and there are

96 studies that suggest that this could be also the case in individuals with SMI diagnoses such as
97 SSD [14]. According to the Strassnig et al. (2014), the loss of physical capability in
98 individuals with schizophrenia could be linked to their increased cardiometabolic risk which
99 can potentially accelerate the ageing process [14].

100 Within this context, it could be hypothesized that multimorbidity drives increased disability
101 in SMI patients. The main aim of this study is therefore, to examine the association between
102 physical multimorbidity and disability in individuals with SMI, considering relevant socio-
103 economic determinants. Our specific objectives were to investigate a) the prevalence of
104 complex multimorbidity in a large representative cohort of individuals with SMI cohort and
105 their association with the exact SMI diagnosis, age at SMI diagnoses, gender, ethnicity and
106 social deprivation; b) the association of physical multimorbidity with level of disability
107 which was measured using the **Health of the Nation Outcome Scale [15] - a 12-scale**
108 **clinician-rated measure of disability which has been developed to measure health and social**
109 **care outcomes in secondary care mental health services for adults between the ages of 18-65**
110 and c) the potential explanatory role of relevant socio-economic determinants in this
111 association.

112 **Methods**

113 **Sample**

114 Patient data were extracted from the Clinical Record Interactive Search (CRIS); a case
115 register system that contains de-identified mental healthcare electronic health record data
116 from the South London and Maudsley Trust NHS Foundation Trust (SLaM). **The CRIS**
117 **system has been developed for use within the National Institute of Health Research (NIHR)**
118 **Maudsley Biomedical Research Centre (BRC) and provides authorised researchers with**
119 **regulated and secure access to anonymous information from South London and Maudsley**
120 **(SLaM) NHS Foundation Trust. SLaM is one of Europe's largest provider of secondary**

121 mental healthcare, serving a geographic catchment of approximately 1.2 million residents,
122 and providing all aspects of secondary mental healthcare to all age groups. Since 2006, full
123 electronic clinical records have been deployed in SLaM, and data from these are accessible
124 via the CRIS system which allows searching and retrieval of anonymized full records for
125 over 500,000 cases currently represented in the system [16]. **SLaM NHS foundation provides**
126 **the widest range of NHS mental health and addiction services within the UK. There are over**
127 **230 services which constitute inpatient wards, outpatient and community services. Over 5000**
128 **people each year and provided inpatient care per year and over 45,000 patients are treated in**
129 **the community across Lambeth, Southwark, Lewisham and Croydon.**

130 Our maximal sample size (N=13933) included all individuals aged 15 years or older who had
131 received a primary or secondary diagnosis of severe mental illness between 2007 and 2018
132 (according to the International Classification of Mental and Behavioural Disorders-10; ICD-
133 10). Specifically, component diagnoses included schizophrenia-spectrum disorders (SSD;
134 ICD-10: F20-F29) and bipolar disorders (BD; ICD-10: F30-F31). Individuals who did not
135 have data available for the total HONOS score or had diagnoses for both SSD and BD were
136 excluded. Excluded individuals were more likely to be slightly younger at age at first SMI
137 diagnoses recorded in CRIS, White British men and residents in less deprived areas
138 (Supplemental Table 1).

139 **Variables**

140 Disability. Disability was measured using Health of the Nation Outcome Scales (HoNOS);
141 [15]. HoNOS is a clinician rated tool developed to measure health and social functioning of
142 individuals with SMI and it includes 12 subscales: ‘overactive, aggressive, disruptive or
143 agitated behaviour; non-accidental self-injury; problem drinking or drug taking; cognitive
144 problems; physical illness or disability problems; problems associated with hallucinations or
145 delusions; problems associated with depression; other mental and behaviour problems;

146 problems with relationships; problems with activities of daily living; problems with living
147 conditions; and problems with occupation and activities [15]. Scores for each sub-category
148 range from 0 to 4; with 0 defined as no problems of this kind during the period rated and 4
149 associated with a severe problem in the category, with the highest impact on the individual.
150 Each score was divided into three categories that have been defined as not present (HoNOS
151 subscale score 0), minimal (score 1) or significant (scores 2-4) [17]. Total HoNOS scores of
152 individuals at the first SMI diagnosis recorded in CRIS were used. Higher scores for HoNOS
153 indicate severe impairment in the individual's mental health and social functioning, which we
154 label in this study as higher levels of disability. We used HoNOS **total adjusted score which**
155 **becomes relevant when one or more subscores have not been recorded by a clinician. To**
156 **prevent the score becoming deceptively low, an algorithm within the electronic patient**
157 **journey system recalculates the total, accounting for the missing values, thereby increasing**
158 **accuracy of the score [18]. This is a standard approach in research using electronic health**
159 **records extracted from the electronic patient journey system.**

160 Physical health conditions. Data on the physical health conditions were extracted using a
161 natural language processing algorithm, **SemEHR [19]. SemEHR is a clinical NLP framework**
162 **that embeds a baseline model for identifying contextualized mentions of biomedical concepts**
163 **from clinical documents. The context information asserts whether a mention is present or**
164 **absent (negation), current or historical, affirmed or hypothetical, related to the patient or**
165 **others (e.g., family history).** This algorithm showed satisfactory performance estimates (F1=
166 0.81 - 0.95) **(details can be found in [20]).** This data extraction strategy made available
167 relevant data to identify whether an individual had a mention of a disease from a specific
168 organ system associated with the following ICD-10 Chapters [21]: Chapter II: neoplasms;
169 Chapter III: anaemia and blood diseases; Chapter IV: endocrine; Chapter VI: nervous system
170 ; Chapter VII; eye and adnexal disorders; Chapter IX: circulatory disorders; Chapter X:

171 respiratory disorders; Chapter XI: digestive disorders; Chapter XII: skin disorders, Chapter
172 XIII: musculoskeletal disorders and finally, Chapter XIV: genitourinary disorders. Complex
173 multimorbidity was defined as having 2 or more organ systems affected besides the SMI
174 diagnoses [22].

175 Covariates. Covariates included age at first recorded SMI diagnosis, sex, ethnicity (British
176 White, Irish White, Black African, Black Caribbean, South Asian (Bangladeshi, Indian and
177 Pakistan) and Chinese), and neighborhood-level deprivation [2,3]. Neighbourhood level
178 deprivation was assessed using the index of multiple deprivation (IMD) 2010 score of an area
179 in which the individual resides. This area was measured according to LSOA11 (lower layer
180 super output area 2011) [23]. An official measure for the deprivation of LSOA11 areas in
181 England ranked each LSOA from 1 (most deprived) to 32,844 (least deprived.) The
182 deprivation measure was based on seven census-derived indicators. Each LSOA area
183 contained approximately 1500 residents or 650 households [24]. The multiple deprivation
184 score is divided into five quintiles, to ensure consistency with previous work [17].

185 Hospitalizations defined as number of admissions for each patient were recorded over the
186 study period.

187 **Statistical procedure**

188 In order to address our first objective, to estimate the prevalence of physical multimorbidity
189 and correlates we performed descriptive analyses and explored associations using chi-
190 squares, T-student and ANOVA tests. Chi-square tests with Bonferroni adjustments for
191 multiple comparisons were conducted when relevant.

192 To investigate the association of complex multimorbidity with level of disability measured
193 using the Health of Nation Outcome Scale (HoNOS) and its subscales and the potential
194 explanatory role of relevant socio-economic determinants in this association (objective 2 and
195 3), we performed series of hierarchical multiple linear regressions. We examined models

196 including independent adjustments for sex (model 2), age (model 3), social deprivation
 197 (model 4), ethnicity (model 5), SMI (model 7) and hospitalizations (model 9), so fully
 198 adjusted models diagnoses with and without SMI (model 6 and model 8).

199 **Results**

200 *Descriptive analyses*

201 As shown in Table 1, 42.1% of our sample was less than 35 years old at the time of their first
 202 SMI diagnoses recorded at SLAM. 52.2% were men, 26.2% were Black, Asian and Minority
 203 Ethnic (BAME), 68.2% were in the higher levels of social deprivation, 61.5% of the cohort
 204 had complex multimorbidity (i.e., SMI and 2 or more organ systems affected) and 54.4%
 205 were hospitalized during the study period (individuals with complex multimorbidity more
 206 likely to have been hospitalized compared to those without complex multimorbidity).
 207 Significant associations were found between complex comorbidity and age at SMI diagnoses
 208 but no significant differences were found for sex, ethnicity or social deprivation. We found
 209 differences by SMI diagnoses; individuals with SSD were more likely to report complex
 210 multimorbidity (62.5%) compared to those diagnosed with BD (58.3%). However, we did not
 211 find any differences for those with an intellectual disability defined as mild intellectual
 212 disability (F7) or developmental disorders (F8).

213

214 **Table 1.** Descriptive statistics for maximal sample size (N=13933), individuals with complex
 215 multimorbidity (n=8569) and without complex multimorbidity (n=5364).

216

	Total cohort n(%)	No complex multimorbidity n(%)	Complex Multimorbidity n(%)	Chi-square tests
		5364 (38.5)	8569 (61.5)	
	13933 (100.0)			

Age at diagnosis	2415 (17.3)	916 (37.9) 1265 (36.5)	1499 (62.1) 2197 (63.5)	$\chi^2 =$ 39.95 (6); $p < .001$
15 – 24	3462 (24.8)	1133 (38.4) 798 (37.3)	1821 (61.6) 1339 (62.7)	
25 – 34	2954 (21.2)	431 (38.7) 423 (42.5)	682 (61.3) 573 (57.5)	
35 – 44	2137 (15.3)	398 (46.5)	458 (53.5)	
45 – 54	1113 (7.99)			
55 – 64	996 (7.15)			
65 – 74	856 (6.14)			
75 +				
Sex				
Male	7267(52.2)	2769 (38.1)	4498 (61.9)	$\chi^2 =$ 0.98 (1); $p = .322$
Female	6665 (47.8)	2595 (38.9)	4070 (61.1)	
Ethnicity				
British White	4755 (34.1)	1862 (39.2) 681 (36.7)	2893 (60.8) 1176 (63.3)	$\chi^2 =$ 5.95 (5); $p = .312$
Black African	1857 (13.3)	479 (39.0) 197 (41.9)	748 (61.0) 273 (58.1)	
Black Caribbean	1227 (8.81)	113 (37.9) 37 (37.0)	185 (62.1) 63 (63.0)	
South Asian	470 (3.37)	1995 (38.2)	3231 (61.8)	
Irish White	298 (2.14)			
Chinese	100 (0.72)			
Unknown	5226 (37.5)			
IMD				
1 (most deprived)	370 (2.66)	151 (40.8)	219 (59.2)	$\chi^2 =$ 2.21 (4); $p = .697$
2	866 (6.22)	327 (37.8)	539 (62.2)	
3	2854 (20.5)	1124 (39.4) 2516 (38.5)	1730 (60.6) 4024 (61.5)	
4	6540 (46.9)	1126 (38.0) 120 (35.1)	1835 (62.0) 222 (64.9)	
5 (least deprived)	2961 (21.3)			
Unknown	342 (2.45)			
SMI Diagnosis				
Schizophrenia spectrum disorder	10554 (75.74)	3954 (37.5) 1410 (41.7)	6600(62.5) 1969(58.3)	$\chi^2 =$ 19.47 (1);

Bipolar Affective Disorder	3379 (24.25)			<.001
Hospitalizations				
Yes	7585 (54.44)	2692 (35.5) 2672 (42.1)	4893 (64.5) 3676 (57.9)	$\chi^2 = 63.317$ (1); $p < .001$
No	6348 (45.56)			
Intellectual Disabilities				
F7: Mild Intellectual Disabilities	288 (2.07) 264 (1.89)	98 (34.0) 94 (35.6)	190 (66.0) 170 (64.4)	$\chi^2 = 2.29$ (1); $p = .130$
F8: Developmental Disorders				$\chi^2 = 0.830$ (1); $p = .362$

217

218 *Note.* Percentages are shown by column for total cohort and by row for sub-groups by
219 complex multimorbidity status.

220 The IMD scores of the patients have been split into quintiles, where quintile 1 is the most
221 deprived and quintile 5 being the least deprived.

222

223 With regards to the organ systems affected, we found that **Chapter VI (nervous system**

224 **disorders) was the most prevalent (n= 4830; 34.7%),** followed by Chapter XII dermatological

225 disorders (n = 2152, 15.4%) and Chapter IX circulatory disorders (n = 2059, 14.8%). For

226 those with BD, neurological disorders (31.9%) were most prevalent, followed by respiratory

227 (14.5%) and musculoskeletal/ connective tissue (13.6%). For patients with SSD, we found

228 neurological disorders (35.5%) again to be most prevalent, followed by dermatological

229 (16.1%) and circulatory disorders (15.8%). **When we explored differences between BD and**

230 **SSD (Table 2), we found significant differences** for chapters III (haematological), IV

231 (endocrine), VI (neurological), VII (eye and adnexal), IX (circulatory) and XII

232 (dermatological). Individuals with SSD had higher mentions of haematological disorders,
 233 endocrine disorders, neurological disorders, eye disorders, circulatory disorders, and
 234 dermatological disorders compared to those with BD.

235

236 **Table 2.** Descriptive statistics for individuals with at least one condition from the following
 237 organ systems (ICD-10 Chapters) in the SMI cohort (N=13933) and individuals with SSD
 238 (n=10554) and BD (n=3379).

239

	Ch. II Neoplastic disorders	Ch. III Haematological disorders	Ch. IV Endocrine disorders	Ch. VI Neurological disorders	Ch. VII Eye and Adnexal disorders	Ch. IX Circulatory disorders	Ch. X Respiratory disorders	Ch. XI Digestive disorders	Ch. XII Dermatological disorders	Ch. XIII Musculoskeletal disorders	Ch. XIV Genitourinary disorders.
All	715 (5.1)	655 (4.7)	1874 (13.5)	4830 (34.7)	1376 (9.9)	2059 (14.8)	2012 (14.4)	1812 (13.0)	2152 (15.4)	2057 (14.8)	633 (4.5)
SSD	533 (5.1)	531 (5.0)	1510 (14.3)	3751 (35.5)	1107 (10.5)	1670 (15.8)	1522 (14.4)	1379 (13.1)	1694 (16.1)	1597 (15.1)	457 (4.3)
BD	182 (5.4)	124 (3.7)	364 (10.8)	1079 (31.9)	269 (8.0)	389 (11.5)	490 (14.5)	433 (12.8)	458 (13.6)	460 (13.6)	176 (5.2)
<i>p-values</i>	>.99	.01	<.001	<.001	<.001	<.001	>.99	>.99	<.001	.176	.198

240 *Note.* SSD = schizophrenia spectrum disorder; BD= bipolar disorder. Percentages are shown
 241 by row, except for the first column. **P-values are shown for differences between SSD and BD.**

242

243 The mean HONOS score of disability at time of first SMI diagnoses recorded, for the whole
 244 SMI cohort was 10.60 (SD=6.14) **which showed an increasing pattern with age.** There were
 245 significant differences in total HONOS scores between patients diagnosed with SSD and BD
 246 (Table 3); individuals with SSD had a higher score on average (SSD=10.95 vs BD=9.49).

247 Significant differences were found for all HoNOS subscales. Patients with SSD were more
 248 likely to report severe cognitive problems, physical illness, activities of daily living,
 249 hallucinations/delusions, relationship problems, occupational problems and problems with
 250 living conditions. On the other hand, individuals with BD were more likely to have severe
 251 problems with agitated behaviours, self-injury, depressed mood, drinking problems and other
 252 mental problems.

253

254 **Table 3.** HONOS total score and subscales for SMI cohort and SSD and BD groups at time
 255 of first SMI diagnoses.

256

	SMI cohort	Schizophrenia Spectrum disorder	Bipolar Disorder	Statistics
N	13933	10554	3379	
HONOS mean (SD)	10.60 (6.14)	10.95(6.18)	9.49 (5.89)	t(2) = 15386809.00; p<.001
Hospitalizations	7585	6070 (57.51)	1337 (39.56)	$\chi^2(1) = 165.36;$ p<.001
Agitated behaviour				
0	7314 (52.5)	5705 (54.1)	1609 (47.6)	
1	3208 (23.0)	2399 (22.7)	809 (23.9)	
2 to 4	3408 (24.5)	2447 (23.2)	961 (28.4)	
Missing	3 (0.0)	3 (0.0)	0 (0.0)	$\chi^2(2) = 50.73;$ p<.001
Self-injury				
0	11797 (84.7)	9142 (86.6)	2655 (78.6)	
1	1151 (8.3)	755 (7.2)	396 (11.7)	
2 to 4	972 (7.0)	646 (6.1)	326 (9.6)	
Missing	13 (0.1)	11 (0.1)	2 (0.1)	$\chi^2(2) = 129.78 ;$ p<.001
Problem drinking				
0	10310 (74.0)	7893 (74.8)	2417 (71.5)	

1	1354 (9.7)	953 (9.0)	401 (11.9)	
2 to 4	2148 (15.4)	1613 (15.3)	535 (15.8)	
Missing	121 (0.9)	95 (0.9)	26 (0.8)	$\chi^2(2)=25.36$; $p<.001$
Cognitive problems				
0	8598 (61.7)	6226 (59.0)	2372 (70.2)	
1	2928 (21.0)	2324 (22.0)	604 (17.9)	
2-4	2372 (17.0)	1971 (18.7)	401 (11.9)	
Missing	35 (0.3)	33 (0.3)	2 (0.1)	$\chi^2(2)=142.49$; $p<.001$
Physical illness				
0	8942 (64.2)	6684 (63.3)	2258 (66.8)	
1	2105 (15.1)	1654 (15.7)	451 (13.3)	
2 to 4	2850 (20.5)	2189 (20.7)	661 (19.6)	
Missing	36 (0.3)	27 (0.3)	9 (0.3)	$\chi^2(2)=15.76$; $p<.001$
Hallucinations				
0	4845 (34.8)	2534 (24.0)	2311 (68.4)	
1	2176 (15.6)	1776 (16.8)	400 (11.8)	
2 to 4	6865 (49.3)	6202 (58.8)	663 (19.6)	
Missing	47 (0.3)	42 (0.4)	5(0.1)	$\chi^2(2)=2283.71$; $p<.001$
Depressed mood				
0	5646 (40.5)	4486 (42.5)	1160 (34.3)	
1	4001 (28.7)	3260 (30.9)	741 (21.9)	
2 to 4	4266 (30.6)	2,792 (26.5)	1474 (43.6)	
Missing	20 (0.1)	16 (0.2)	4 (0.1)	$\chi^2(2)=360.09$; $p<.001$
Other mental problems				
0	3766 (27.0)	3011 (28.5)	755 (22.3)	
1	2819 (20.2)	2185 (20.7)	634 (18.8)	
2 to 4	7281 (52.3)	5311 (50.3)	1,970 (58.3)	
Missing	67 (0.5)	47 (0.4)	20 (0.6)	$\chi^2(2)=72.23$; $p<.001$
Relationship Problems				
0	5339 (38.3)	3904 (37.0)	1435 (42.5)	
1	3631 (26.1)	2733 (25.9)	898 (26.6)	

2 to 4	4875 (35.0)	3844 (36.4)	1031 (30.5)	
Missing	88 (0.6)	73 (0.7)	15 (0.4)	$\chi^2(2)= 45.97$; $p<.001$
Daily living problems				
0	7191 (51.6)	5188 (49.2)	2003 (59.3)	
1	3040 (21.8)	2344 (22.2)	696 (20.6)	
2 to 4	3620 (26.0)	2960 (28.0)	660 (19.5)	
Missing	82 (0.6)	62 (0.6)	20 (0.6)	$\chi^2(2)= 125.26$; $p<.001$
Living conditions				
0	8468 (60.8)	6086 (57.7)	2382 (70.5)	
1	2277 (16.3)	1812 (17.2)	465 (13.8)	
2 to 4	2788 (19.9)	2346 (22.2)	442 (13.1)	
Missing	400 (2.9)	310 (2.9)	90 (2.7)	$\chi^2(2)= 194.23$; $p<.001$
Occupational problems				
0	6343 (45.5)	4523 (42.9)	1820 (53.9)	
1	3123 (22.4)	2436 (23.1)	687 (20.3)	
2 to 4	4134 (29.7)	3320 (31.5)	814 (24.1)	
Missing	333 (2.4)	275 (2.6)	58 (1.7)	$\chi^2(2)= 122.783$; $p<.001$

257 **Note. T-tests and chi-squares were used to examine differences between SSD and BD with**
258 **Bonferroni adjustments for multiple comparisons.**

259

260 *Association between multimorbidity and disability*

261 When we investigated whether there were differences in the HoNOS subscales between those
262 individuals having complex multimorbidity and those that did not have complex
263 multimorbidity (Table 4), we did not find significant differences for overall HoNOS scores
264 and subscales except for difficulties with hallucinations which seem to be more likely in
265 individuals with complex multimorbidity. We further examined the association between
266 complex multimorbidity and HoNOS total scores using multiple linear regressions and we

267 found that although there was a positive trend it was only significant when adjusting for age
 268 (Supplemental Table 2).

269

270 **Table 4.** HONOS total score and subscales for SMI cohort and complex vs not complex
 271 multimorbidity for the whole cohort (N=13933).

	No Complex Multimorbidity	Complex Multimorbidity	Statistics
N (%)	5364 (38.5)	8569 (61.5)	
HONOS mean (SD)	10.49 (6.12)	10.67 (6.16)	$t(2) = 22617650.50$; $p=.057$
Agitated behaviour			
0	2821 (52.6)	4493 (52.4)	
1	1241 (23.1)	1967 (23.0)	
2 to 4	1300 (24.2)	2108 (24.6)	
Missing	2 (0.0)	1 (0.0)	$\chi^2(2) = 0.24$; $p>.99$
Self-injury			
0	4561 (85.0)	7236 (84.4)	
1	445 (8.3)	706 (8.2)	
2 to 4	353 (6.6)	619 (7.2)	
Missing	5 (0.1)	8 (0.1)	$\chi^2(2) = 2.10$; $p>.99$
Problem drinking			
0	3998 (74.5)	6312 (73.7)	
1	508 (9.5)	846 (9.9)	
2 to 4	806 (15.0)	1342 (15.7)	
Missing	52 (1.0)	69 (0.8)	$\chi^2(2) = 1.74$; $p>.99$
Cognitive problems			
0	3321 (61.9)	5277 (61.6)	
1	1108 (20.7)	1820 (21.2)	
2-4	920 (17.2)	1452 (16.9)	
Missing	15 (0.3)	20 (0.2)	$\chi^2(2) = 0.67$; $p >.99$
Physical illness			
0	3381 (63.0)	5561 (64.9)	
1	810 (15.1)	1295 (15.1)	
2 to 4	1156 (21.6)	1694 (19.8)	
Missing	17 (0.3)	19 (0.2)	$\chi^2(2) = 6.91$; $p = .192$
Hallucinations			
0	1964 (36.6)	2881 (59.5)	
1	804 (15.0)	1372 (16.0)	

2 to 4	2575 (48.0)	4290 (50.1)	
Missing	21 (0.4)	26 (0.3)	$\chi^2(2) = 13.55; p = .006$
Depressed mood			
0	2166 (40.4)	3480 (40.6)	
1	1553 (29.0)	2448 (28.6)	
2 to 4	1640 (30.6)	2626 (30.6)	
Missing	5 (0.1)	15 (0.2)	$\chi^2(2) = 0.22; p > .99$
Other mental problems			
0	1507 (28.1)	2259 (26.4)	
1	1034 (19.3)	1785 (20.8)	
2 to 4	2795 (52.1)	4486 (52.4)	
Missing	28 (0.5)	39 (0.5)	$\chi^2(2) = 7.64; p = .132$
Relationship Problems			
0	2072 (38.6)	3267 (38.1)	
1	1418 (26.4)	2213 (25.8)	
2 to 4	1845 (34.4)	3030 (35.4)	
Missing	29 (0.5)	59 (0.7)	$\chi^2(2) = 1.56; p > .99$
Daily living problems			
0	2831 (52.8)	4360 (50.9)	
1	1124 (21.0)	1916 (22.4)	
2 to 4	1378 (25.7)	2242 (26.2)	
Missing	31 (0.6)	51 (0.6)	$\chi^2(2) = 5.57; p = .372$
Living conditions			
0	3269 (60.9)	5199 (60.8)	
1	887 (16.5)	1390 (16.2)	
2 to 4	1057 (19.7)	1731 (20.2)	
Missing	151 (2.8)	249 (2.9)	$\chi^2(2) = 0.64; p > .99$
Occupational problems			
0	2508 (46.8)	3835 (44.8)	
1	1199 (22.4)	1924 (22.5)	
2 to 4	1528 (28.9)	2586 (30.2)	
Missing	109 (2.0)	224 (2.6)	$\chi^2(2) = 4.73; p = .564$

272 **Note.** T-tests and chi-squares were used to examine differences between SSD and BD with
273 Bonferroni adjustments for multiple comparisons.

274

275

276 Furthermore, we explored the associations between each specific organ systems considered in
 277 this study and HoNOS, total score and its subscales (Supplemental Table 3 and Tables 4).
 278 Summarized results are shown in Figure 1 for significant associations between HoNOS
 279 subscales and specific organ systems in models adjusted for sex and age are shown in black.
 280 All associations which were not significant have not been shaded. (Supplemental Tables 4).
 281

Agitated behaviour		p = .023	p < .001			p < .001	p < .001	p = .033	p = .040	p < .001	
Self-injury				p < .001				p = .018	p = .010		
Problems eating or sleep								p < .001			
Cognitive problems			p < .001	p < .001	p < .001	p < .001	p < .001	p < .001	p < .001		
Physical illness	p < .001	p < .001	p < .001	p < .001	p < .001	p < .001	p < .001	p < .001	p < .001	p < .001	p < .001
Hallucinations		p < .001	p < .001	p < .001	p < .001	p < .001			p < .001	p < .001	
Depressed mood	p < .001	p < .001		p < .001							p = .012
Other mental problems											p = .014
Relationship problems			p < .001				p < .001		p < .001	p < .001	
ADLs problems			p < .001	p < .001	p < .001	p < .001	p < .001	p < .001	p < .001	p < .001	
Living condition problems		p < .001								p = .012	p = .010
Occupational problems		p < .001	p < .001				p < .001	p < .001		p < .001	
	Chapter II: Neoplastic disorders	Chapter III: Haematological disorders	Chapter IV: Endocrine disorders	Chapter V: Neurological disorders	Chapter VI: Eye & adnexal disorders	Chapter VII: Circulatory disorders	Chapter VIII: Respiratory disorders	Chapter IX: Digestive disorders	Chapter X: Dermatological disorders	Chapter XI: Musculoskeletal connective tissue disorders	Chapter XII: Genitourinary disorders

282
 283 We found that having at least one disorder from some specific organ systems is associated
 284 with higher probabilities of reporting difficulties with the disability dimensions captured by
 285 HoNOS subscales (See supplemental Tables 4 and Figure 1). The organ systems that showed
 286 higher number of HoNOS domains affected are in decreasing order: nine HoNOS domains in
 287 individuals with musculoskeletal disorders (Chapter XIII); eight in those with
 288 skin/dermatological (Chapter XII); seven domains in those with comorbid endocrine (Chapter
 289 IV) or respiratory disorders (Chapter X); six for those with comorbid hematological (Chapter
 290 III), neurological (Chapters VI) or circulatory disorders (Chapter IX); five for individuals
 291 with comorbid digestive disorders (Chapter XI); four for those with eye and adnexal
 292 disorders (Chapters VI and VII); two and one domain for those individuals with comorbid
 293 neoplasms (Chapter II) and genito-urinary disorders (Chapter XIV), respectively.

294 Individuals with comorbid musculoskeletal disorders (Chapter XIII), compared to those
 295 without these musculoskeletal disorders, are more likely to report difficulties with agitated
 296 behavior, cognitive function, physical illnesses, hallucinations, depressed mood, other mental

297 health problems, relationship problems, ADLs and living problems (unadjusted models). All
298 these associations were found to be strengthened after taking in consideration age and sex
299 potential confounding except for cognitive problems depressed mood which were partially
300 attenuated after adjustments. Individuals with comorbid skin/dermatological disorders
301 (Chapter XII), compared to those without these specific comorbid disorders, are more likely
302 to report difficulties with agitated behaviors, cognitive problems, physical illnesses,
303 hallucinations, relationship problems, ADLs, living conditions and occupational problems
304 (unadjusted models). All these associations were found to be strengthened after taking in
305 consideration age and sex potential confounding except for problems with hallucinations
306 which were fully attenuated after adjusting for age and sex.

307 Individuals with comorbid endocrine disorders (Chapter IV), compared to those without
308 comorbid endocrine diseases, are more likely to report difficulties with agitated behaviors,
309 cognitive problems, physical illnesses, hallucinations, relationship problems, ADLs and
310 occupational problems (unadjusted models). All these associations were found to be
311 strengthened after taking in consideration age and sex potential confounding. Individuals
312 with comorbid respiratory diseases (Chapter X) compared to those without comorbid
313 respiratory diseases are more likely to report difficulties with agitated behavior, self-injury,
314 drinking problems, cognitive problems, physical illnesses, relationship problems, ADL and
315 occupational problems (unadjusted models). These associations were strengthened for
316 difficulties associated with agitated behaviors, cognitive problems, physical illness,
317 relationship problems, ADLs and occupational problems, and partially attenuated for
318 drinking problems and nearly fully attenuated for difficulties associated with self-injury when
319 age and sex adjustments were considered.

320 Individuals with comorbid neurological diseases (Chapter VI), compared to those without
321 neurological diseases, are more likely to report difficulties with self-injury, cognitive

322 problems, physical illnesses, hallucinations, depressed mood and ADLs (unadjusted models).
323 All these associations (except self-injury) were partially attenuated after adjusting for age and
324 sex. Individuals with comorbid circulatory diseases (Chapter IX), compared to those without
325 circulatory diseases, are more likely to report difficulties with agitated behavior, drinking
326 problems, self-injury, cognitive problems, physical illnesses, hallucinations, depressed mood,
327 ADLs and occupational problems (unadjusted models). All these associations (except
328 occupational problems) were partially attenuated after adjusting for age and sex.

329 Overall, most individuals who have at least one condition from the organ systems considered
330 in this study report difficulties with ADLs, hallucinations and cognitive problems and these
331 cannot be fully explained by the normative ageing process. Most individuals with diseases
332 from the specific organ systems considered in this study showed also a consistent higher
333 probability of difficulties associated with physical illness which provides evidence supporting
334 the adequate performance of our data extraction strategy.

335 *Ad hoc analyses*

336 We performed analyses to consider those individuals that had both SSD and BD diagnoses
337 (Supplemental Table 5) and we found that they had similar demographic characteristics that
338 our study cohort. Individuals with both SMI diagnoses (Mean HoNOS=10.22, SD=6.39)
339 reported lower levels of disability than those with only SSD [Mean=10.95, SD=6.18;
340 $t(11448)= 167.13; p<.001$] but greater than those with only BD [Mean=9.49, SD=5.89;
341 $t(11539)= 148.89; p<.001$]. Moreover, we also performed analyses focusing only on the
342 SSD group (n=10554) which showed significant differences in HoNOS score between
343 individuals with and without complex multimorbidity so as for specific ICD-chapters
344 (Supplementary Table 6).

345 **Discussion**

346 This study aimed to investigate the association between recorded physical multimorbidity and
347 disability in individuals with SMI, considering relevant socio-economic correlates. Our first
348 objective was to estimate the prevalence of physical multimorbidity in a large representative
349 cohort of individuals with SMI and their association with age at SMI diagnosis, nature of
350 SMI diagnosis, gender, ethnicity, and social deprivation. Our results showed that 61.5% of
351 the cohort had complex multimorbidity, which in the context of this study is a SMI diagnosis
352 with comorbidities of 2 or more organ systems. With regards to the specific organ systems
353 affected in the whole SMI cohort and the SSD subgroup, we found that the systems most
354 commonly affected were those that could be categorized within the ICD-10 Chapter VI -
355 nervous system disorders (34.7%), Chapter XII - dermatological disorders (15.4%) and
356 Chapter IX - circulatory disorders (14.8%). These results for the whole SMI cohort and the
357 SSD subgroup are in line with previous research in which has found nervous system
358 disorders very highly prevalent in these patients [8,17] as well as cardiovascular comorbidity
359 [24]. For the BD subgroup, neurological disorders were also the most common (31.9%) but
360 respiratory disorders (14.5%) were second most common instead followed by
361 musculoskeletal disorders (13.6%). These findings are also partially consistent with previous
362 research which has found COPD a common comorbidity in population diagnosed with
363 psychotic disorders [25]. However, other authors have found COPD more prevalent in SSD
364 compared to BD [26]. Future research exploring potential differences associated with
365 respiratory disease comorbidities in SSD and BD are still needed. With regards to the high
366 prevalence of musculoskeletal / connective tissue disorders in the BD subgroup, previous
367 research has found lower bone mineral density and greater prevalence of osteoporosis in
368 individuals with SMI diagnoses including BD. This link has been associated with risk factors
369 such as patients' lifestyle like smoking, alcohol abuse, vitamin D and calcium deficiency

370 alongside the use of antipsychotics [27] and further research in this direction would be of
371 interest.

372 When we explored the disability measured with HoNOS and its subscales, there were
373 significant differences in HONOS scores between patients diagnosed with SSD and BD. Our
374 findings showed a greater prevalence of depressive symptoms and other mental health issues
375 within the BD subgroup. Similar findings have also been found in previous research with BD
376 patients which show high prevalence of depression in primary care settings [28], positive
377 correlation between depressive symptoms and the number of organ systems affected [29] and
378 specifically, depressive symptoms have been also found to be associated with greater levels
379 of disability in individuals with chronic health conditions [30]. Research comparing these
380 associations in individuals with BD and SSD are still scarce and therefore our findings with
381 this respect are not directly comparable with previous research.

382 When we investigated the association between complex multimorbidity and disability the
383 results were not as clear as when we explored the independent association of physical
384 conditions and HoNOS scores and subscales. Although we found a positive trend in the
385 association between complex multimorbidity and disability, it was only significant when
386 adjusting for age. These findings could suggest that when we are considering a general
387 measure of complex multimorbidity in this cohort (more than 2 physical health comorbidities
388 beyond mental health comorbidities), we might be focusing on the unhealthiest and therefore
389 those with higher levels of disability, which in turn are more likely to be the oldest of the
390 cohort. In addition, HoNOS total score might not be as informative of the functioning levels
391 of individuals with SMI diagnoses compared to the information that can be extracted from its
392 subscales.

393 With regards to the association between each specific organ system and HoNOS subscales
394 which represent relevant disability domains, our results indicated that there was a greater

395 variability among organ systems affected which provides evidence to support using specific
396 HoNOS domains rather total composite scores. Specifically, organ systems reflecting
397 comorbid respiratory, endocrine, musculoskeletal, skin/dermatological, neurological or eye
398 and adnexal disorders were found to be associated with significant difficulties associated with
399 more than five HoNOS domains while others had a lower number of domains affected. This
400 finding not only confirm that individuals with SMIs with physical comorbidities are at greater
401 risk of overall disability, as suggested by previous research in non-SMI populations [13] and
402 SMI populations [31,32] but also highlights the relevance of the differential impact of each
403 specific organ system affected. Physical comorbidities associated with musculoskeletal,
404 skin/dermatological, respiratory, endocrine, circulatory, neurological or hematological
405 systems seem to have a greater impact on functioning levels compared to physical
406 comorbidities categorized as neoplasms, eye, digestive or genito-urinary disorders. Although
407 not directly comparable, our findings are in line with previous research has found that
408 specific conditions that can be categorized as musculoskeletal [13]. Although cardiovascular
409 comorbidities (circulatory diseases) are highly prevalent in this population [27] and
410 individuals with these were found to have higher total HoNOS scores compared to those
411 without these comorbidities in the present study; individuals with circulatory diseases do not
412 have a very high number of HoNOS subdomains affected. Overall, most individuals who
413 have at least one condition from the organ systems considered in this study report difficulties
414 with ADLs, hallucinations and cognitive problems and these cannot be fully explained by the
415 functional decline driven by the normative ageing process.

416 One of the main strengths of this study was the large and diverse sample of individuals with
417 severe mental illness which allowed us to provide us novel and original findings in these
418 traditionally neglected population in multimorbidity research. In addition, we unlocked
419 hidden data on physical health conditions from clinical text to facilitate further our

420 understanding of the physical comorbidities in this population which is transferable to other
421 mental health trusts in the UK and therefore can facilitate and promote future research in the
422 topic using this type of EHRs. Our data source allowed us to have a key indicator of
423 functioning in these patients which is a widely collected measure in these services, HoNOS,
424 which provides us a unique opportunity for future cross-cohort comparisons.

425 Some limitations should be also acknowledged. Although our data extraction was quite
426 comprehensive, some systems such as ear related disorders which were not available given to
427 limitations of the natural language processing algorithm [19,20] and we mainly focus on
428 system level data (ICD-10 Chapters) rather than specific health conditions. Therefore, future
429 studies should consider widening the number of systems considered and developing strategies
430 that allow to extract and identify specific health conditions at more granular level using this
431 type of records. **When we examined specific ICD-chapters, we compared those individuals
432 with a diagnoses from a specific ICD-10 chapter to those individuals without diagnoses of
433 that specific ICD-10 chapter. This might provide us limited information between ICD-10
434 chapters and therefore further research is needed to detangle further the independent impact
435 of each system affected.** It should be acknowledged that although HoNOS is considered a
436 good proxy for disability other specific and more objective measures could be also of interest
437 for comparison purposes. Future studies should also consider measures such as walking speed
438 or grip strength which are physical functioning measures known to predict mortality or
439 specific cognitive functioning instruments which were unfortunately unavailable in our study.
440 **Furthermore, although we considered hospitalizations as a proxy of severity, we recognize
441 that this data has limited interpretability considering the nature of our data source with this
442 respect and further research is needed to explore the impact of duration and severity of SMI
443 in this population. Finally, both SSD and Bipolar have varying treatments; for example, the
444 first-line management of SSD involves antipsychotic such as aripiprazole, while treatment-**

445 resistant schizophrenia involves use of clozapine [33]. Use of antipsychotics can lead to
446 subsequent side-effects such as weight gain, uncontrollable movements such as tics and
447 tremors, seizures and clozapine also comes with a risk of agranulocytosis which reduces
448 patients' abilities to fight infections [34]. Bipolar disorder is managed by mood stabilizing
449 drugs like lithium as well as antipsychotics [35]. There is a range of first-line treatments for
450 both SSD and BD which can result in a range of side effects and may impact physical health
451 of patients. As we haven't controlled for medications being used by patients, this is a
452 limitation of the study. Future studies exploring the impact of antipsychotics on comorbidities
453 of patients with SMI will be invaluable.

454 To sum up, our findings are useful and relevant to identify individuals with SMI which might
455 be at high risk of disability. Although we found that older individuals with higher number of
456 organ systems affected beyond their mental health conditions (complex multimorbidity) are
457 more likely to have higher levels of disability compared to those with that cannot be
458 considered as having complex multimorbidity (SMI with none or a single organ system
459 affected), our results highlighted the differential impact that each specific organ systems
460 affected has on disability. Moreover, our findings have provided evidence that domain
461 specific measures of disability measures, rather than composite total scores as indicators, can
462 be more informative to understand the association between physical multimorbidity and
463 disability in research focusing on SMI population. To sum up, we have found that: a)
464 individuals with complex multimorbidity should be targeted for prevention and intervention
465 programs aimed to reduce disability in this population; b) individuals with SMI and physical
466 comorbidities that could be categorized as musculoskeletal, skin/dermatological, respiratory,
467 endocrine, neurological or circulatory disorders are at higher risk of disability compared to
468 individuals with SMI that do not have those physical comorbidities; and c) individuals with
469 SMI and physical health comorbidities are at greater risk of reporting difficulties associated

470 with ADLs, hallucinations and cognitive problems. Therefore, policies aiming to reduce
471 disability in SMI populations should prioritize those with musculoskeletal,
472 skin/dermatological, respiratory, endocrine, neurological or circulatory disorders; and
473 prevention and intervention programs should be targeted to reduce difficulties with ADLs,
474 hallucinations and cognitive problems. Although these results cannot be directly compared
475 with previous research as the association between SMI and complex multimorbidity with
476 disability has not been widely investigated; previous research has also suggested a greater
477 level of cognitive impairment in patients with SSD, which might be leading to lower levels of
478 functioning [33]. Future research should further explore the potential mediator role of
479 cognition in this association, with other potential confounders such as obesity, physical
480 activity or smoking.

481

482 **Data availability statement:** Due to the confidential nature of free-text data, we are unable
483 to make patient-level data available. This project was approved by the CRIS Oversight
484 Committee which is responsible for ensuring all research applications comply with ethical
485 and legal guidelines. The CRIS system enables access to anonymised electronic patient
486 records for secondary analysis from SLAM and has full ethical approvals. CRIS was
487 developed with extensive involvement from service users and adheres to strict governance
488 frameworks managed by service users. It has passed a robust ethics approval process
489 acutely attentive to the use of patient data. Specifically, this system was approved as a
490 dataset for secondary data analysis on this basis by Oxfordshire Research Ethics Committee
491 C (08/H06060/71). The data is de-identified and used in a data-secure format and all patients
492 have the choice to opt-out of their anonymized data being used. Approval for data access
493 can only be provided from the CRIS Oversight Committee at SLAM.

494

495 **Conflict interest statements:** No conflict of interests to disclose.

496

497 **References**

- 498 1. Navickas R, Petric V-K, Feigl AB, Seychell M. Multimorbidity: What Do We Know?
499 What Should We Do? *Journal of Comorbidity*. 2016;6:4–11.
- 500 2. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of
501 multimorbidity and implications for health care, research, and medical education: a
502 cross-sectional study. *The Lancet* [Internet]. 2012;380:37–43. Available from:
503 [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(12\)60240-2/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60240-2/fulltext)
- 504 3. Cassell A, Edwards D, Harshfield A, Rhodes K, Brimicombe J, Payne R, et al. The
505 epidemiology of multimorbidity in primary care: a retrospective cohort study. *British*
506 *Journal of General Practice* [Internet]. 2018;68:e245–51. Available from:
507 <https://bjgp.org/content/68/669/e245>
- 508 4. Kuan V, Denaxas S, Gonzalez-Izquierdo A, Direk K, Bhatti O, Husain S, et al. A
509 chronological map of 308 physical and mental health conditions from 4 million
510 individuals in the English National Health Service. *The Lancet Digital Health*.
511 2019;1:e63–77.
- 512 5. Ashworth M, Durbaba S, Whitney D, Crompton J, Wright M, Dodhia H. Journey to
513 multimorbidity: longitudinal analysis exploring cardiovascular risk factors and
514 sociodemographic determinants in an urban setting. *BMJ Open* [Internet]. 2019 [cited
515 2020 May 2];9:e031649. Available from:
516 <https://bmjopen.bmj.com/content/bmjopen/9/12/e031649.full.pdf>
- 517 6. Sauver JLS, Boyd CM, Grossardt BR, Bobo WV, Rutten LJF, Roger VL, et al. Risk
518 of developing multimorbidity across all ages in an historical cohort study: differences
519 by sex and ethnicity. *BMJ Open* [Internet]. 2015;5:e006413. Available from:
520 <https://bmjopen.bmj.com/content/5/2/e006413>

- 521 7. Smith DJ, Martin D, McLean G, Langan J, Guthrie B, Mercer SW. Multimorbidity in
522 bipolar disorder and undertreatment of cardiovascular disease: a cross sectional study.
523 BMC Medicine. 2013;11.
- 524 8. Woodhead C, Ashworth M, Schofield P, Henderson M. Patterns of physical co-/multi-
525 morbidity among patients with serious mental illness: a London borough-based cross-
526 sectional study. BMC Family Practice. 2014;15.
- 527 9. Hjorthøj C, Stürup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life
528 expectancy in schizophrenia: a systematic review and meta-analysis. The Lancet
529 Psychiatry [Internet]. 2017;4:295–301. Available from:
530 [https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366\(17\)30078-0/fulltext](https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(17)30078-0/fulltext)
- 531 10. Das-Munshi J, Chang C-K, Dutta R, Morgan C, Nazroo J, Stewart R, et al. Ethnicity
532 and excess mortality in severe mental illness: a cohort study. The Lancet Psychiatry.
533 2017;4:389–99.
- 534 11. Nowak I, Sabariego C, Świtaj P, Anczewska M. Disability and recovery in
535 schizophrenia: a systematic review of cognitive behavioral therapy interventions.
536 BMC Psychiatry [Internet]. 2016 [cited 2019 Apr 15];16. Available from:
537 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940955/>
- 538 12. Kisely S, Campbell LA, Cartwright J, Cox M, Campbell J. Do the Health of the
539 Nation Outcome Scales Measure Outcome? The Canadian Journal of Psychiatry.
540 2010;55:431–9.
- 541 13. Quiñones AR, Markwardt S, Botosaneanu A. Multimorbidity Combinations and
542 Disability in Older Adults. The Journals of Gerontology Series A, Biological Sciences
543 and Medical Sciences [Internet]. 2016 [cited 2020 Dec 13];71:823–30. Available
544 from: <https://pubmed.ncbi.nlm.nih.gov/26968451/>

- 545 14. Strassnig M, Signorile J, Gonzalez C, Harvey PD. Physical performance and
546 disability in schizophrenia. *Schizophrenia Research: Cognition*. 2014;1:112–21.
- 547 15. Wing JK, Curtis RH, Beevor AS. Health of the Nation Outcome Scales (HoNOS).
548 *British Journal of Psychiatry*. 1999;174:432–4.
- 549 16. Stewart R, Soremekun M, Perera G, Broadbent M, Callard F, Denis M, et al. The
550 South London and Maudsley NHS Foundation Trust Biomedical Research Centre
551 (SLAM BRC) case register: development and descriptive data. *BMC Psychiatry*.
552 2009;9.
- 553 17. Kugathasan P, Wu H, Gaughran F, Nielsen RE, Pritchard M, Dobson R, et al.
554 Association of physical health multimorbidity with mortality in people with
555 schizophrenia spectrum disorders: Using a novel semantic search system that captures
556 physical diseases in electronic patient records. *Schizophrenia Research* [Internet].
557 2019 [cited 2020 Sep 10]; Available from:
558 [https://vbn.aau.dk/en/publications/association-of-physical-health-multimorbidity-](https://vbn.aau.dk/en/publications/association-of-physical-health-multimorbidity-with-mortality-in-p)
559 [with-mortality-in-p](https://vbn.aau.dk/en/publications/association-of-physical-health-multimorbidity-with-mortality-in-p)
- 560 18. Gale TM, Boland B. A model for predicting missing items on the Health of the Nation
561 Outcome Scale (HoNOS). *Comprehensive Psychiatry*. 2019 Aug;93:61–4.
- 562 19. Wu H, Toti G, Morley KI, Ibrahim ZM, Folarin A, Jackson R, et al. SemEHR: A
563 general-purpose semantic search system to surface semantic data from clinical notes
564 for tailored care, trial recruitment, and clinical research. *J Am Med Inform Assoc*.
565 2018 Jan 19;25(5):530–7.
- 566 20. Bendayan R, Wu H, Kraljevic Z, Stewart R, Searle T, Chaturvedi J, et al. Identifying
567 physical health comorbidities in a cohort of individuals with severe mental illness: An
568 application of SemEHR. arXiv:200208901 [cs] [Internet]. 2020; Available from:
569 <http://arxiv.org/abs/2002.08901>

- 570 21. Jackson TJ, Michel JL, Roberts R, Shephard J, Cheng D, Rust J, et al. Development
571 of a validation algorithm for “present on admission” flagging. *BMC Medical*
572 *Informatics and Decision Making*. 2009;9.
- 573 22. Harrison C, Britt H, Miller G, Henderson J. Examining different measures of
574 multimorbidity, using a large prospective cross-sectional study in Australian general
575 practice. *BMJ Open*. 2014;4:e004694–4.
- 576 23. Heslin M, Khondoker M, Shetty H, Pritchard M, Jones PB, Osborn D, et al. Inpatient
577 use and area-level socio-environmental factors in people with psychosis. *Social*
578 *Psychiatry and Psychiatric Epidemiology*. 2018;53:1133–40.
- 579 24. Osborn DPJ, Wright CA, Levy G, King MB, Deo R, Nazareth I. Relative risk of
580 diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with
581 severe mental illnesses: systematic review and metaanalysis. *BMC psychiatry*
582 [Internet]. 2008 [cited 2021 Feb 21];8:84. Available from:
583 <https://pubmed.ncbi.nlm.nih.gov/18817565/>
- 584 25. Schneider F, Erhart M, Hewer W, Loeffler LA, Jacobi F. Mortality and medical
585 comorbidity in the severely mentally ill—a German registry study. *Deutsches*
586 *Aerzteblatt Online*. 2019;
- 587 26. Partti K, Vasankari T, Kanervisto M, Perälä J, Saarni SI, Jousilahti P, et al. Lung
588 function and respiratory diseases in people with psychosis: Population-based study.
589 *The British Journal of Psychiatry* [Internet]. 2015;207:37–45. Available from:
590 [https://www.cambridge.org/core/journals/the-british-journal-of-](https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/lung-function-and-respiratory-diseases-in-people-with-psychosis-populationbased-study/C3DFE25AFBC4AD8D366C567D473069C9)
591 [psychiatry/article/lung-function-and-respiratory-diseases-in-people-with-psychosis-](https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/lung-function-and-respiratory-diseases-in-people-with-psychosis-populationbased-study/C3DFE25AFBC4AD8D366C567D473069C9)
592 [populationbased-study/C3DFE25AFBC4AD8D366C567D473069C9](https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/lung-function-and-respiratory-diseases-in-people-with-psychosis-populationbased-study/C3DFE25AFBC4AD8D366C567D473069C9)
- 593 27. Correll CU, Solmi M, Veronese N, Bortolato B, Rosson S, Santonastaso P, et al.
594 Prevalence, incidence and mortality from cardiovascular disease in patients with

- 595 pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768
596 patients and 113,383,368 controls. *World Psychiatry*. 2017;16:163–80.
- 597 28. McIntyre RS, Calabrese JR. Bipolar depression: the clinical characteristics and unmet
598 needs of a complex disorder. *Current Medical Research and Opinion*. 2019;35:1993–
599 2005.
- 600 29. Kemp DE, Gao K, Chan PK, Ganocy SJ, Findling RL, Calabrese JR. Medical
601 comorbidity in bipolar disorder: relationship between illnesses of the
602 endocrine/metabolic system and treatment outcome. *Bipolar Disorders*. 2010;12:404–
603 13.
- 604 30. Sheridan PE, Mair CA, Quiñones AR. Associations between prevalent multimorbidity
605 combinations and prospective disability and self-rated health among older adults in
606 Europe. *BMC Geriatrics*. 2019;19.
- 607 31. Desalegn D, Girma S, Tessema W, Yeshigeta E, Kebeta T. Quality of Life and
608 Associated Factors among Patients with Schizophrenia Attending Follow-Up
609 Treatment at Jimma Medical Center, Southwest Ethiopia: A Cross-Sectional Study.
610 *Psychiatry Journal*. 2020;2020:1–7.
- 611 32. McIntyre RS, Konarski JZ, Soczynska JK, Wilkins K, Panjwani G, Bouffard B, et al.
612 Medical Comorbidity in Bipolar Disorder: Implications for Functional Outcomes and
613 Health Service Utilization. *Psychiatric Services*. 2006;57:1140–4.
- 614 33. **BMJ. Schizophrenia - Symptoms, diagnosis and treatment | BMJ Best Practice**
615 **[Internet]. bestpractice.bmj.com. 2021. Available from:**
616 **<https://bestpractice.bmj.com/topics/en-gb/3000091?q=Schizophrenia&c=suggested>**
- 617 34. **The National Institute of Mental Health Information Resource Center. NIMH» Mental**
618 **Health Medications [Internet]. www.nimh.nih.gov. 2016. Available from:**
619 **<https://www.nimh.nih.gov/health/topics/mental-health-medications>**

- 620 35. BMJ. Bipolar disorder in adults - Symptoms, diagnosis and treatment | BMJ Best
621 Practice [Internet]. bestpractice.bmj.com. 2020. Available from:
622 <https://bestpractice.bmj.com/topics/en-gb/488>
- 623 36. University of Bath. Indices of Multiple Deprivation (IMD) Lookup Guide [Internet].
624 Available from: [https://www.bath.ac.uk/publications/undergraduate-bursaries-and-](https://www.bath.ac.uk/publications/undergraduate-bursaries-and-scholarships-terms-and-conditions-2020-21/attachments/Indices-of-Multiple-Deprivation-Lookup-Guide.pdf)
625 [scholarships-terms-and-conditions-2020-21/attachments/Indices-of-Multiple-](https://www.bath.ac.uk/publications/undergraduate-bursaries-and-scholarships-terms-and-conditions-2020-21/attachments/Indices-of-Multiple-Deprivation-Lookup-Guide.pdf)
626 [Deprivation-Lookup-Guide.pdf](https://www.bath.ac.uk/publications/undergraduate-bursaries-and-scholarships-terms-and-conditions-2020-21/attachments/Indices-of-Multiple-Deprivation-Lookup-Guide.pdf)